Calculation of the therapeutic activity of radioiodine 131 I for individualized dosimetry in the treatment of Graves' disease requires an accurate estimate of the thyroid absorbed radiation dose based on a tracer activity administration of 131 I. Common approaches (Marinelli-Quimby formula, MIRD algorithm) use, respectively, the effective half-life of radioiodine in the thyroid and the time-integrated activity. Many physicians perform one, two, or at most three tracer dose activity measurements at various times and calculate the required therapeutic activity by ad hoc methods. In this paper, we study the accuracy of estimates of four 'target variables': time-integrated activity coefficient, time of maximum activity, maximum activity, and effective half-life in the gland. Clinical data from 41 patients who underwent 131 I therapy for Graves' disease at the University Hospital in Pisa, Italy, are used for analysis. The radioiodine kinetics are described using a nonlinear mixed-effects model. The distributions of the target variables in the patient population are characterized. Using minimum root mean squared error as the criterion, optimal 1-, 2-, and 3-point sampling schedules are determined for estimation of the target variables, and probabilistic bounds are given for the errors under the optimal times. An algorithm is developed for computing the optimal 1-, 2-, and 3-point sampling schedules for the target variables. This algorithm is implemented in a freely available software tool. Taking half-life in the thyroid and measurement noise, the optimal 1-point time for time-integrated activity coefficient is a measurement 1 week following the tracer dose. Additional measurements give only a slight improvement in accuracy.
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Introduction
Radioiodine 131 I therapy is used in the treatment of Graves' disease to reduce the thyroid mass and impact the hyperthyroid state. In some 80% of cases, however, the patient becomes irreversibly hypothyroid (Brent 2008) , thus, in effect, replacing one condition by another, albeit a less severe one. There is considerable variety in determining the appropriate radioiodine activity to be administered, both between and within countries, and even between and within hospitals (Jönsson and Mattsson 2004) , and continuing debate (Kalinyak and McDougall 2003, Carlier et al 2006) about which method is best for determining the thyroid absorbed dose. It is plausible that individualized dosing could achieve the desired therapeutic effect with less radioactivity, result in less radioactive waste released into the environment, and improve the chance of inducing a prolonged euthyroid (rather than hypothyroid) state. Such individualized dosing requires accurate estimates of the total absorbed dose in the thyroid, the main issue addressed in this paper. Because of restrictions on resources, time, labor, and patient availability, usually no more than three, and, more commonly, only one or two activity measurements are performed. Indeed, current clinical practice in the United States consists of one measurement at 24 h, although some physicians also take a measurement at around 6 h.
Common approaches to calculating the required therapeutic activity of 131 I for thyroid diseases are the original Marinelli-Quimby (MQ) formula (Marinelli et al 1948) and the currently preferred MIRD algorithm (Bolch et al 2009) . Either way, it is usually assumed that the thyroid mass remains constant during the period when 131 I remains active in the thyroid and we follow this assumption. The original MQ formula, based on an exponential decay model (Quimby and Feitelberg 1963) , involves the administered radioiodine activity, A 0 , the maximum fractional thyroid uptake, denoted by U max , and the effective half-life of 131 I in the thyroid of the individual patient, T eff . Note that in this paper we have adopted the most recent nomenclature as in MIRD pamphlet n.21 (Bolch et al 2009) . The MIRD approach uses instead the time-integrated activityÃ(T, ∞) of radioiodine activity A (T, t) in the thyroid, where T denotes thyroid, i.e. the time integral of the activity (Bolch et al 2009) :
The explicit formula forÃ(T, ∞) depends on which model of radioiodine kinetics in the thyroid is adopted. The MIRD formula for the absorbed dose D MIRD in the thyroid is
where S(T ← T, t) is the absorbed dose rate per unit activity (Bolch et al 2009) . In this paper we consider instead the time-integrated activity coefficientã(T, ∞) of radioiodine activity in the thyroid (Bolch et al 2009) :
The four quantitiesã(T, ∞), T max (time of maximum activity), U max (maximum fractional thyroid uptake), and T eff , which we shall refer to as our 'target variables', are of interest beyond Graves' disease. They are important in general radiation dosimetry and pharmacokinetics studies; in the latter case 'activity' is often replaced by 'concentration'. Thus our methods pertain to a wide range of dosimetric and biokinetic applications.
Motivated by the initial results in (Merrill 2008) , in this paper, starting with clinical patient data, we characterize the reference population (to which the results of the study will apply) using a nonlinear mixed-effects (NLME) model for the radioiodine kinetics. From the estimated parameters for this population, we simulate a set of fictitious or 'virtual' patients whose individual parameters, both fixed and random effects, are known. This large simulated sample is used to study the accuracy of estimates of the target variables obtained with different sampling schedules consisting of one, two, or three measurement times. We use the root mean squared error (RMSE), which incorporates both bias and estimation error variability, as the optimality criterion to determine optimal 1-, 2-, and 3-point schedules. Descriptive statistics are employed to examine other aspects of the distributions of the estimation errors, including probabilistic bounds on the size of the errors under the optimal times.
Reference population and governing relations
Activity data on 41 patients who underwent 131 I therapy for Graves' disease at the University Hospital in Pisa, Italy, were analyzed retrospectively to characterize the reference population. Details of the enrollment and measurement procedures have been published previously Xhafa 2009, Traino et al 2004) . Following the application of a therapeutic 131 I activity, each patient had between five and nine (with the exception of two patients with four) activity measurements performed over a period of about a month.
The data were fit with a standard two-compartment model (DiMartino et al 2002) , the compartments being the thyroid gland and circulation. The differential equations for this model are readily solved for the fraction of administered activity in the thyroid compartment at time t(h):
where U(t) ≡ a(T, t) is the measured fraction of administered activity in the thyroid compartment (Bolch et al 2009) , and Y, B, C are the patient-specific parameters reflecting individual uptake, biological half-life, and clearance rates. In what follows, the term 'activity' refers to U. The parameters Y, B, and C, which vary from patient to patient, are positive, and, because the activity is normalized, Y < 1. In biokinetic models, such parameters are often found to have skewed, often lognormal, population distributions (Rowland and Tozer 2010). Equation (1) is called the structural model, and Y, B, and C the structural parameters. Based on (1), the time to maximum activity, T max , and the maximum fractional thyroid uptake, U max ≡ a(T, T max ), are given by 
which is the form we shall use. From (1), the time-integrated activity coefficientã(T, ∞) =Ã(T, ∞)/A 0 can be expressed asã
Thus, once the parameters Y, B, and C are known (or estimated), the target variablesã(T, ∞), T max , U max , and T eff can be calculated. We now introduce the mixed-effects structure. The observed activity is assumed to follow (1) subject to a multiplicative error,
where ε has the normal distribution with mean 0 and variance σ 2 . This error structure is commonly found in pharmacological studies, and corresponds to a constant coefficient of variation. The source of error in this context is the measurement error ε, which depends on the instruments and techniques used to acquire the measurements, and has the same statistical properties for all patients. These errors are assumed to be independent for different measurement occasions and from patient to patient. If the magnitudes of the errors are small, 1 + ε can be approximated by exp(ε); then taking (natural) logarithms of (5) yields
which is in a convenient form for NLME analysis. Standard practice (Pinheiro and Bates 2000) in NLME is to rewrite (6) as
where y = log(− log(Y )), b = log(B), and c = log(C). This forces Y, B, and C to be positive and enables the NLME estimation algorithm to use unconstrained optimization. The double log ensures that Y < 1. The individual patient parameters are modeled as y = y f +y r , b = b f +b r , and c = c f + c r . Here y f , b f , c f are the fixed effects, which represent the average values of the parameters (on log scale) over the whole population, and y r , b r , c r are the random effects representing the deviations of the individual's parameters from the population average. 'Mixed effects' refers to the presence of both fixed and random effects. The random-effects vector (y r , b r , c r ) is modeled as multivariate normal, N(0, ), i.e. with mean vector 0 and variance/covariance matrix , independent of the measurement errors ε, and independent between patients. Inserting the expressions for y, b, and c into (7) we obtain
where
Optimization of sampling times
The reference population is characterized by the estimated fixed effects y f , b f , c f , the matrix , the measurement error variance σ 2 , from the analysis of the original patient data, all of which are taken as known, and appropriate normality assumptions 6 . The characterization of the reference population is used as the basis for a parametric bootstrap simulation of N = 1000 fictitious or 'virtual' patients whose individual parameters, i.e. fixed effects and random effects, are known. These virtual patients will constitute a random sample of N subjects drawn from the (conceptually infinite) reference population. To keep things straight, we shall refer to our original data set of 41 'real' patients as RP41 and our virtual patients as VP1000. First, a vector of random effects (y * r , b * r , c * r ) is generated from the N(0, ) distribution for each simulated patient. From these, individual parameters y * , b * , and c * are obtained, and a(T, ∞), T max , U max , and T eff are calculated using (2a), (2b), (3), and (4), respectively; we will attach an asterisk to designate these values, e.g.ã(T, ∞) * . They are the 'true' target values for the VP1000 patients.
In addition to the random effects, measurement errors are simulated from the N(0, σ 2 ) distribution for each patient and each candidate measurement time. Now, given an m-point sampling schedule d m (m = 1, 2, or 3), consisting of measurement times t 1 , t 2 , . . . , t m , we create log-activity data u(t i ) = log(U sim (t i )) at those times for all the virtual patients, using (7) or (8) with the known values of y f , b f , c f , the matrix , the simulated ε errors, and simulated random effects for each patient. The result is the (simulated) activity, U sim , data set for all N virtual patients at the measurement times t 1 , t 2 , . . . , t m , such as one might encounter in clinical practice. The random effects for each patient are then estimated from these 'virtual clinical data' as the conditional mode, i.e. the value of (y r , b r , c r ) that maximizes the conditional density of the random effects given the log-activity data (Pinheiro and Bates 2000, Lindstrom and Bates 1990) . This conditional density is given (using standard probability notation) by
Only the numerator on the right-hand side above enters into the maximization; thus,
Given the random effects y * r , b * r , c * r , the u(t i ) data are independent normal with mean
) and variance σ 2 , and, because is diagonal (see section 4), the random effects are independent normal, mean 0, with variances denoted by ω The estimation bias, Bias, is the average estimation error, and the variability of the estimation error is measured by the variance, Var. Thus RMSE, which incorporates bias and variance, is a simple and interpretable measure of the quality of estimation, and we use it as the optimality criterion. The optimal m-point schedule for a target variable is the one that minimizes the RMSE; it may be different for each of the targets.
We restricted the candidate measurement times to t = [2, 4, 6, 12, 24, 48, 72, 96, 168] h. These times were chosen because they are typically used in practice; they are a subset of the times considered by Merlé et al (1993 Merlé et al ( , 1994 . The upper limit of 168 h (= 7 d) was chosen since the primary utility of this work ultimately would be to determine a therapeutic activity of 131 I based on a tracer activity from which the patient-specific structural parameters would be estimated. Each 1-point schedule is of the form We determine the optimal 1-, 2-, and 3-point schedules for all the target variables. We use histograms and boxplots to visualize the error distributions when the optimal times are used, and plot the RMSE as a function of the times to see how the criterion varies over all the candidate times. Finally, tolerance intervals (TIs) (Guttman et al 1971) are employed to give probabilistic bounds on the size of the errors under the optimal schedules.
Results

Characterization of the reference population
Estimates of the fixed effects y f , b f , c f , the standard deviations (SDs) ω y , ω b , ω c of the random effects, and the residual or measurement error SD from the NLME analysis of the original RP41 data and (8) are given in table 1 (we performed the preliminary analysis of the patient data using MATLAB (The Mathworks 2009)). The corresponding values of the fixed effects are Y f = 0.7942, B f = 0.0054, C f = 0.4142. The variance/covariance matrix of the random effects was fit both as a diagonal matrix, corresponding to independence of the random effects y r , b r , c r , and as a full matrix with no restriction on its structure except that it be symmetric and positive definite. A likelihood ratio test of the null hypothesis ' diagonal' against the alternative ' full' failed to reject the null; therefore, we take = diag ω to their individual parameters Y, B, C. The figure illustrates how the individual subjects' activity curves (black line) vary around the 'fixed' or population curve (blue-dashed line), which is the same for all patients.
The NLME residuals, which approximate the errors, were tested for normality both visually and with a formal statistical test. The normal probability plot of the residuals (not shown) suggests normality except for the presence of a few outliers. The estimates of σ with and without the outliers were very similar; the value 0.1156 in table 1 is the latter and is consistent with measurement errors reported in the literature (Stabin 2008 , Pacilio et al 2009 . In conjunction with normality, a SD of 0.1156 implies that most measurement errors will be < 0.25; thus, the approximation leading from (5) to (6) is valid.
Optimal sampling times
The optimality criterion RMSE is a function of the time points in the sampling schedule. Figure 2 shows plots of the RMSE as functions of t 1 for all the 1-point schedules for each of the target variablesã(T, ∞), T max , U max , and T eff . The optimal 1-point schedule for T max is [2] h, whereas [168] h is the optimal 1-point schedule for bothã(T, ∞) and T eff . On the other hand, [24] h and [48] h are both optimal for U max . Similarly, the optimal 2-and 3-point schedules can be picked out visually from figures 3 and 4, but, more importantly, the figures show how the criterion function RMSE varies with different choices of measurement times. In fact, to choose favorable sampling times and to assess accuracy of measurements taken at times other than the candidate times used in this paper, one could follow the patterns suggested in figures 2-4.
The values of RMSE allow us to give an interval that captures 75% (or other desired fraction) of the estimation errors under any sampling schedule. A slight modification of Chebychev's inequality (Guttman et al 1971) for the estimation error Q for any target variable Q gives
for any value of k > 0, with Pr standing for 'probability of'. For k = 2, (12) says that the magnitude of Q is at most 2 · RMSE with probability at least 0.75. In short, the interval ±2 · RMSE contains (at least) 75% of the values of Q. Generally ±2 · RMSE is a crude bound; the TIs described next usually give much tighter bounds. Table 2 shows the optimal 1-, 2-, and 3-point schedules along with the corresponding RMSEs and 95% TIs (confidence coefficient 94%) for the population of errors in each case. The TIs are of the form (p2%, p98%), where, e.g., p2% is the 2% percentile of the distribution of 'observed' errors Q; the confidence level is based on a standard approximation (Guttman et al 1971) . We also show TI values as a percentage of the corresponding mean, TI(%). Thus, for example, with a high level (94%) of confidence, we can assert that, using the optimal 2-point schedules, in 95% of patients, we will not underestimateã(T, ∞) by more than 23.54 h or overestimateã(T, ∞) by more than 41.38 h. By comparison, ±2 · RMSE = 29.54 h is the 75% interval from (12), so the lower limit is worse than that of the 95% TI based on percentiles. In many instances, given the potential seriousness of Graves' disease, a rapid turnaround time is needed to enhance clinical decision making. The often-preferred sampling times at 4 and 24 h may not be optimal but are clinically practical. For this 2-point sampling schedule, the estimated RMSEs (and error TIs) ofã(T, ∞), T max , U max , and T eff are 27.2(−39.83, 67.89), 3.81(−7.32, 9.51), 0.06(−0.09, 0.13), and 23.11(−39.39, 52.98), respectively.
Illustrative example
To illustrate the application of (11) in the estimation of patient-specific activity parameters and target variables, let us consider patient 2 with the measured activity data shown in table 3.
The fitted activity data are shown in figure 1 and the estimated fixed effects are given in table 1. To solve (11), we also need variances of the random effects and residual SD, all shown in table 1. This optimization can be carried out for 1, 2, or any number of data points. For example, using the data at t = 120, the optimization problem is This problem can be readily solved using a number of free and commercially available software. We have developed a stand-alone software for this purpose that is available for free from the corresponding author. A screen capture of the software is shown in figure 5 . Table 4 shows the estimates of the target variables for patient 2 for various 1-, 2-, and 3-point sampling schedules, obtained with this software. Note that, given the actual data of this patient, it is not possible to achieve optimal 2-and 3-point schedules for some target variables.
Nevertheless, the estimates are (with the exception of T max for 1-point schedule) within the corresponding error TIs in table 2, and, as one adds measurements, they become better.
Discussion
Several models have been used to describe the biokinetics of 131 I in the thyroid (Carlier et al 2006 , Areberg et al 2005 and to compute a(T, ∞) orã(T, ∞) for the purpose of activity determination in connection with the Marinelli-Quimby formula or the MIRD algorithm (Carlier et al 2006) . Areberg et al (2005) used an NLME model based on (1), but with additive rather than multiplicative error, to describe radioiodine kinetics in a population of hyperthyroid patients in Sweden. The diagnoses for these patients were diffuse goiter, multinodular goiter, adenoma, and 'undefined' but not explicitly Graves' disease. Their model also included the covariates, age, diagnosis, and thyroid volume. The structural parameters Y, B, C (in our notation) for an 'average' (over the covariates) member of their population were Y = 0.66, B = 0.0033, C = 0.3167. The fixed effects Y f , B f , C f (without covariates) were 0.53, 0.0035, 0.4055, whereas ours were 0.79, 0.0054, 0.4142, respectively. The numerical differences are likely due in part to the different diagnoses of the two patient groups, the different error models, and perhaps geographical differences. Areberg et al (2005) did not give results on absorbed dose, nor did they address optimal sampling times. Their measurements were made at t = [3, 24, 48] h, and once more between 3 and 9 days later. Hermanska et al (2001) used a model that, although not physiologically motivated, was chosen as a compromise between an overly simple exponential decay model and more complicated compartmental models. Their work was aimed at estimating absorbed doses to postsurgical thyroid remnants. The parameters were estimated by least squares, individually for 704 thyroid carcinoma patients.Ã(T, ∞) was computed numerically and compared with calculated values using an exponential decay model for tracer and therapeutic activities of 131 I. Hermanska et al (2001) concluded that their compromise model was superior to exponential decay but required at least a non-practical number of six measurements.
To our knowledge, the only work on optimal sampling times for radioiodine therapy of Graves' disease is that of Merlé et al (1993 Merlé et al ( , 1994 . Using a Bayesian approach and a compartmental model with five structural parameters, they determined optimal sampling times having one, two, or three measurements at candidate times [1, 2, 4, 6, 12, 24, 48, 72, 96, 168, 192, 216] h. Their optimality criterion was maximization of the information supplied by the experiment (Lindley 1956) , which is based on the concept of Shannon information. This criterion does not directly address either parameter or target value precision or accuracy, although one would expect both to be achieved better with experiments that contain 'more information'. The 1-, 2-, and 3-point schedules forã(T, ∞) using their information criterion were [2], [2, 168], and [1, 12, 216] h. Given prior information, i.e. from a reference population, individual parameter values andã(T, ∞) (NAUC in their notation) values were obtained from maximum a posteriori (MAP) estimates. The mean value (and SD) in their reference population was 132.00 h (36.33), similar to 137.61 h (39.46) in ours. Additional measurements increase the information criterion function and decrease the preposterior SD ofã(T, ∞), which Merlé et al (1994) used as a separate criterion for estimation quality, but they did not discuss the estimation error distribution further. The fact that their optimal times are not nested clouds the interpretation of this result, although their figure 3 shows that [2, 12, 168] h is nearly information-optimal. Our table 2 also suggests that, forã(T, ∞), [2, 12, 168] h is close to optimal for the RMSE and widens the TI only slightly. Their 1-point information-optimal schedule [2] is the worst-case schedule forã(T, ∞) using the RMSE criterion. The largest decrease in preposterior SD comes when t = 168 h is added to the 1-point schedule, which is plausible in view of our results.
Our results are summarized in table 2 and figures 2-4. For all the target variables, it is surprising how much accuracy is achieved with only one measurement. Of course it is crucial that there be information available from an initial patient database that allows for the estimation of the fixed effects and the variance/covariance matrix of the random effects. For more than one measurement, the best gain in accuracy is obtained in going from one to two measurements; adding a third measurement gives only a slight additional gain in accuracy. These findings are consistent with those of Merlé et al (1993 Merlé et al ( , 1994 although our approach and optimality criteria differ from theirs. The RMSE forã(T, ∞) with the optimal 1-point schedule was 16.8 h, about 12% of the mean time-integrated activity. The corresponding results for U max and T eff were similar (10% and 15%), but not for T max (42%). Based on TIs, the range of errors forã(T, ∞) using the optimal 1-point schedule went from an underestimate of 26 h (19%) to an overestimate of 42 h (31%). The optimal 3-point schedule forã(T, ∞) had an RMSE of 11% and only slightly better than even the 1-point schedule. The gain in accuracy for T eff follows the same pattern (table 2) , showing only a modest improvement in going from one to three measurements.
Many authors (e.g. Berg et al (1996) ) have commented on the need for a late activity measurement after a tracer activity of 131 I in order to determine the proper therapeutic activity using Marinelli-Quimby (MQ) type calculations. This is reflected in our results for T eff andã(T, ∞), which are the main ingredients of the MQ-type and MIRD-based calculations. Indeed, the 1-point optimal times forã(T, ∞) and T eff are both 168 h, the latest possible time among our candidate times. As suggested by these results, the 1-point time largely determines the achievable accuracy for these two target variables with up to three measurements using the method proposed in this paper.
The gains in accuracy for T max and U max in going from 1-point to 2-point schedules are rather more dramatic. For T max the optimal 1-point RMSE is 5.3 h (42%), and the TI is from −13.3 to 12.8 h (−106% to 102%), whereas the corresponding 2-point results are RMSE = 2.46 h (20%), TI: −4.1 to 6.0 h (−33% to 48%). The 3-point gain is more modest: RMSE = 2.25 h, TI: −4.0 to 5.0 h (−32% to 40%). The pattern for U max is similar. The difference between T eff andã(T, ∞) on one hand and T max and U max on the other is discussed below.
The significance of early and late measurements, especially forã(T, ∞) and T eff , can be seen from (6). Rewriting it, we have 1
For a 'late' measurement at time t L we have B ≈ − 1 t L log(U obs (t L )), with equality in the limit as t L → ∞, whereas for an 'early' measurement t E , such as t E = 2 or 6 h, the logarithmic and error terms in (13) throw off the estimate of B. Thus, with a single late measurement t L we can estimate B, and therefore also T eff = log(2)/B; hence, there is little benefit in a measurement in addition to t L for T eff . The SDs in table 1 show, however, that estimating B using only (13), without any information from the reference population, will be unsatisfactory unless t L is impractically large.
As in (4),ã(T, ∞) = Y C B (B+C) . Clearlyã(T, ∞) is sensitive to the parameter B. By contrast,ã(T, ∞) is relatively insensitive to C, as can be seen by looking at the 95% TI, from 0.0682 to 2.5168 for C (based on table 1); the corresponding interval for B is from 0.0038 to 0.0076. If B is accurately estimated by a late measurement t L , an early measurement t E would provide little information for estimatingã(T, ∞) beyond knowledge of the fixed-effect value C f .
The situation is slightly more complicated for the other target variables. The sensitivities of T max and U max to early and late measurements can be developed along the same lines, based on (2a)-(2b). These target variables are sensitive to both B and C, so an additional measurement will have a more substantial effect. A more formal approach is also possible (Morgan and Henrion 1996) .
Conclusions
There are differing techniques for determining the appropriate dose of 131 I for the treatment of Graves' disease. Given a considerable level of measurement noise, clinicians are faced with the problem of quantifying the uncertainty in estimating key activity variables. To study this uncertainty, we described the radioiodine kinetics using a nonlinear mixed-effects model framework and showed that by choosing the measurement times appropriately one can optimize probabilistic bounds on the accuracy of the corresponding estimates. The optimal 1-point sampling times for time-integrated activity and effective half-life are the same, i.e. take the measurement as late as possible. Of course, taking into account 131 I effective half-life in the thyroid and measurement noise implies late measurement around 1 week. The inclusion of an earlier measurement time results in only a minor improvement in accuracy. In contrast, two measurements are required for accurate estimation of maximum uptake and time of maximum uptake; a third measurement results in a small additional improvement. Our methodology allows for the design of an individually tailored 131 I therapeutic dosage with quantified estimate of accuracy with at most three activity measurements after a tracer activity. This methodology is very general and can be applied to many areas of biokinetics and dosimetry.
